Detalhe da pesquisa
1.
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
Lancet Oncol
; 17(12): 1653-1660, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27825636
2.
Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines.
Proc Natl Acad Sci U S A
; 108(39): 16375-80, 2011 Sep 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-21930909
3.
Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC.
J Thorac Oncol
; 19(5): 732-748, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38154514
4.
Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy.
Cancer Discov
; 14(6): 965-981, 2024 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38315003
5.
HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
J Thorac Oncol
; 19(1): 106-118, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37678511
6.
Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas.
bioRxiv
; 2024 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38766189
7.
Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy.
bioRxiv
; 2023 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36798379
8.
Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.
J Thorac Oncol
; 18(9): 1165-1183, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37182602
9.
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.
Nat Cancer
; 4(9): 1345-1361, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37743366
10.
Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors.
Mol Cancer Ther
; 21(2): 336-346, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34907086
11.
MET Exon 14 Splice-Site Mutations Preferentially Activate KRAS Signaling to Drive Tumourigenesis.
Cancers (Basel)
; 14(6)2022 Mar 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35326531
12.
Desmoplastic small round cell tumor cancer stem cell-like cells resist chemotherapy but remain dependent on the EWSR1-WT1 oncoprotein.
Front Cell Dev Biol
; 10: 1048709, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36506091
13.
Salt-Inducible Kinase 1 is a potential therapeutic target in Desmoplastic Small Round Cell Tumor.
Oncogenesis
; 11(1): 18, 2022 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35443736
14.
MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer.
Mol Cancer Res
; 20(5): 722-734, 2022 05 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35149545
15.
CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma.
Cancer Res
; 82(6): 1110-1127, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35074756
16.
Functional impact and targetability of PI3KCA, GNAS, and PTEN mutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation.
Cold Spring Harb Mol Case Stud
; 8(1)2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35012940
17.
MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression.
NPJ Precis Oncol
; 6(1): 88, 2022 Nov 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36418460
18.
Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.
Oncogene
; 41(21): 2973-2983, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35459782
19.
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.
Cancer Discov
; 12(5): 1233-1247, 2022 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35135829
20.
Characterization of a small molecule inhibitor of disulfide reductases that induces oxidative stress and lethality in lung cancer cells.
Cell Rep
; 38(6): 110343, 2022 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35139387